ASCEND-2: A Canary in a Coal Mine for Descending to Second-Line Treatment for ALK-rearranged Non-Small Cell Lung Cancer

Translational Lung Cancer Research - Hong Kong
doi 10.21037/tlcr.2016.12.01
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

AME Publishing Company

Related search

Anaplastic Lymphoma Kinase (ALK) Inhibitors for Second-Line Therapy of Non-Small Cell Lung Cancer

Lung Cancer: Targets and Therapy
Oncology
2012English

The Treatment Choice Based on Radiographic Features for Metastatic Brain Tumors in ALK-Rearranged Non–small Cell Lung Cancer

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2017English

Alectinib and Brigatinib: New Second-Generation ALK Inhibitors for the Treatment of Non–Small Cell Lung Cancer

Journal of the Advanced Practitioner in Oncology
2018English

Docetaxel Monotherapy as Second-Line Treatment for Pretreated Advanced Non-Small Cell Lung Cancer Patients

Korean Journal of Internal Medicine
Internal Medicine
2007English

Treatment Paradigms for Patients With Metastatic Non-Small-Cell Lung Cancer: First-, Second-, and Third-Line

Current Oncology
Oncology
2012English

Molecular Mechanisms of Resistance to First- And Second-Generation ALK Inhibitors in ALK-rearranged Lung Cancer

European Journal of Cancer
Cancer ResearchOncology
2016English

The Biology and Treatment of EML4-ALK Non-Small Cell Lung Cancer

European Journal of Cancer
Cancer ResearchOncology
2010English

ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time

Cancer Cell
Cancer ResearchOncologyCell Biology
2010English

Cost-Effectiveness of ALK Testing and First-Line Crizotinib Therapy for Non-Small-Cell Lung Cancer in China

PLoS ONE
Multidisciplinary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy